Home›Vendor Reviews›Peptide Sciences Review

Peptide Sciences Review: What Our Scoring Revealed Before the Shutdown

Updated March 23, 2026 · 10 min read

On March 6, 2026, Peptide Sciences shut down after more than a decade in business. The Henderson, NV-based vendor carried 100+ research peptides, pulled in $7.4 million per month in revenue, and served over a million monthly sessions. Domain registered in 2009, operational for over 15 years, with peak traffic exceeding a million monthly sessions. Then a three-sentence notice replaced the entire site.

This peptide sciences review applies our 5-signal methodology to 123 independently tested samples across 10 peptides from the Peptide Sciences catalog. The overall picture: strong legacy compounds, critical failures on newer products, and one confirmed counterfeit. Some signals pointed to a vendor that earned its reputation. Others pointed directly at what went wrong.

One critical note: peptidessciences.com (plural “sciences”) is a completely different entity with no verified connection to the original. See our full vendor profile for the complete scoring breakdown.

1. Our Methodology Score: Where Peptide Sciences Landed

Peptide Sciences earned a mixed record under our 5-signal methodology. Here is where the scores fell across each signal.

COA verification. Peptide Sciences published COAs, but MagellanRx noted these came from internal testing only, not independent labs. Internal-only COAs are a yellow flag. A vendor grading its own homework is not the same as third-party verification. This gap is also how counterfeit product reached customers unchecked. See our full breakdown of why this matters.

Third-party testing. Finnrick tested 123 samples across 10 Peptide Sciences products. Legacy peptides like Ipamorelin scored an A (9.2/10). Newer high-demand compounds like CJC-1295 scored an E (4.3/10). The inconsistency across the catalog is the problem.

Pricing transparency. Premium pricing across the board, with BPC-157 10mg at roughly $100 when competitors sell at $29–39 for equal or better tested product. No volume discounts or loyalty pricing justified the gap.

Business practices. Ten-year track record counts for something. But the abrupt shutdown with zero customer communication and no refund guidance erased most of that goodwill overnight.

Catalog quality. Deep catalog, 100+ peptides spanning research staples and newer compounds. Breadth was a genuine strength. Whether quality control kept pace with that expansion is the question the testing data answers below.

2. Third-Party Testing: The Finnrick Data That Mattered

Finnrick's independent testing of Peptide Sciences products tells a story of two vendors in one. The legacy peptides held up. The newer, high-demand compounds did not.

Ipamorelin scored an A with a 9.2/10 average across 9 independent tests. Clean, verified, no issues. PT-141 also earned an A at 9.1/10 across 6 tests. BPC-157 landed at A with a 7.8/10 over 13 tests, solid if not exceptional. GHK-Cu scored a B (8.1/10, 6 tests).

Now the other side of the catalog.

Semaglutide dropped to B (7.5/10, 15 tests). Melanotan II scored C (6.4/10, 10 tests). Tirzepatide fell to D (6.3/10, 15 tests). These are the GLP-1 and high-demand compounds where vendor quality separates quickly.

The failures were worse than inconsistent. CJC-1295 scored E at 4.3/10 across 10 tests, a significant quality failure for a widely-used growth hormone secretagogue. Tesamorelin scored E (4.9/10) though only 2 tests limits that sample.

Retatrutide earned an E (6.1/10) across 37 samples, and the problems went beyond low scores. In November 2025, batch IDs RET7920231109-6 and RET7920231124-6 were flagged as containing no retatrutide whatsoever. Counterfeit product, sold at premium prices, caught only by independent community testing.

The pattern across all 123 samples is consistent. Peptides with mature supply chains and years of manufacturing precedent scored well. Peptides with surging demand, higher margins, and murkier sourcing failed. Internal-only COA testing meant no independent checkpoint existed to catch these failures before product shipped.

3. Pricing: Premium Costs Without Premium Guarantees

Peptide Sciences charged premium prices. BPC-157 5mg ran $59.50. The 10mg vial was $100. TB-500 5mg cost $85. PT-141 10mg ran $55. Across popular peptides, pricing ran 40–65% above market rates.

Competitors with equal or better third-party testing results charged significantly less. Skye Peptides sells 10mg BPC-157 in the $29–39 range with batch-specific COAs from named labs.

Premium pricing is defensible when a vendor backs it with consistent independent verification across the entire catalog. Peptide Sciences did not. Internal-only COAs and E-grade scores on newer peptides undercut the pricing argument.

Andrew Huberman publicly flagged that Peptide Sciences accepted Venmo payments. For a vendor billing itself as the premium option in the research peptide space, a peer-to-peer payment app raised questions about operational maturity. Whether that specific detail mattered to regulators is unclear, but it signals the kind of informality that draws attention. On retatrutide, customers paid premium prices for confirmed counterfeits.

4. The Shutdown: March 6, 2026

At approximately 2PM Eastern on March 6, 2026, the Peptide Sciences website went dark. The entire product catalog, account system, and order history were replaced by a three-sentence shutdown notice. No product pages. No account access. No way to retrieve past orders or contact support.

No refund guidance. No email to existing customers. No timeline for processing outstanding orders. Customer accounts with stored payment information and order histories became inaccessible overnight. Anyone with an active order or pending shipment was left with no communication channel and no recourse.

A $7.4 million per month operation went from fully operational to gone in a single afternoon. That afternoon came after 15 months of escalating regulatory pressure across the entire grey-market peptide industry. The speed and silence of the closure stood out even against that backdrop.

The shutdown was not without precedent. Seven or more grey-market vendors closed during 2025, several following FDA enforcement actions. Cremieux publicly warned that the company might attempt to reopen under a different brand name, a pattern already observed with other shuttered vendors. For customers with outstanding orders, no recourse process has been communicated as of this writing.

5. Why It Closed: FDA Enforcement and Pharma Lawsuits

Peptide Sciences did not shut down in isolation. It closed during the most aggressive regulatory sweep the peptide industry has seen. Here is the timeline.

December 2024. FDA issued warning letters to Prime Peptides, Xcel Peptides, SwissChems, and Summit Research. The message was direct: grey-market peptide sales were now an enforcement priority.

January 2025. The ITC issued a General Exclusion Order blocking tirzepatide imports, cutting off a major supply pipeline for grey-market vendors.

April 2025. Eli Lilly filed lawsuits targeting peptide vendors selling GLP-1 receptor agonists.

June 2025. FDA raided Amino Asylum's facilities, the first physical enforcement action.

August 2025. Novo Nordisk filed its own round of lawsuits against peptide vendors, naming 14 defendants in a single filing.

September 2025. FDA issued 50+ warning letters to GLP-1 compounders in a single wave. Reports confirmed the FDA was deploying AI tools to scrape vendor websites for compliance violations.

Criminal cases ran parallel. Tailor Made Compounding forfeited $1.79 million. All American Peptide faced $3 million or more in penalties. Paradigm Peptides entered guilty pleas in December 2025. Seven or more grey-market vendors shut down in 2025 alone. Chinese peptide imports had doubled to $328 million, and independent analyses found 40% of online peptides contained incorrect dosages.

The key distinction. FDA targeted GLP-1 compounds hardest. Semaglutide, tirzepatide, and retatrutide drew the most aggressive action. Peptide Sciences sold all three.

6. The RFK Reversal: 14 Peptides Coming Back to Legal Compounding

On February 27, 2026, RFK Jr. announced on the Joe Rogan podcast that 14 of 19 Category 2 peptides would be moved to Category 1. The affected compounds include BPC-157, TB-500, CJC-1295, Ipamorelin, AOD-9604, Selank, and Semax. These were Peptide Sciences' core catalog.

Category 1 classification does not mean over-the-counter access. It means licensed compounding pharmacies can produce these peptides with a physician's prescription. You will need a doctor and a licensed compounder.

The timing creates an uncomfortable irony. Peptide Sciences shut down on March 6, barely a week after the regulatory environment started moving in a more favorable direction. Whether the company was already too deep into legal exposure to benefit from the shift is unknown, but the sequence matters.

Formal FDA publication of the reclassification was still pending as of March 2026. Until that publication, the regulatory status remains in limbo. For researchers looking forward, this reclassification means licensed compounding pharmacies will be the legal path to many of the same peptides Peptide Sciences carried. Check our vendor directory for current alternatives.

Domain Copycat Warning: peptidessciences.com Is Not Peptide Sciences

This needs to be stated plainly. The domain peptidessciences.com (note the plural “sciences”) is not the same entity as the original peptidesciences.com (singular). Do not assume any relationship between the two.

The plural domain carries a 2.2 out of 5 Trustpilot rating across 23 reviews. A second domain, peptidesciences.org, has also been flagged on Scamadviser. Before closing, Peptide Sciences explicitly warned customers about copycat operations using similar domains.

Cremieux warned that the Peptide Sciences brand may attempt to reopen under a new name or through a different entity. Verify domain spelling character by character. Check Trustpilot review histories for age and consistency. Use vendors scored through a transparent methodology rather than brand recognition from a company that no longer exists.

The Bottom Line

Peptide Sciences built something real over 10+ years. The legacy catalog tested well under independent verification. Ipamorelin (A, 9.2/10), PT-141 (A, 9.1/10), and BPC-157 (A, 7.8/10) were genuinely strong research products backed by consistent batch results.

But the record on newer peptides tells a different story. E-grade scores on CJC-1295, Retatrutide, and Tesamorelin. Confirmed counterfeit batches containing zero active compound. Internal-only COAs across the catalog that functioned as marketing, not verification.

Premium pricing added insult. BPC-157 10mg at $100 when competitors delivered equal or better verified product at $29–39. The pricing reflected reputation, not testing infrastructure.

The abrupt shutdown with no customer communication sealed the assessment. A vendor that disappears overnight with millions in outstanding orders, no refund process, and no contact path has failed a basic trust signal. Whatever the legal pressures, the execution of the exit was a final data point.

For researchers looking for alternatives, Skye Peptides and BioLongevity Labs both carry strong third-party testing records at lower price points. The RFK reclassification may also open licensed compounding pharmacy options within the year. Browse the full vendor directory to compare scores across our 5-signal methodology.

FAQ

Is Peptide Sciences legit?

It was a real company operating out of Henderson, NV for over 10 years. Third-party testing confirmed strong legacy peptides (Ipamorelin scored 9.2/10). Newer compounds showed serious quality failures, including confirmed counterfeit retatrutide.

Is Peptide Sciences still open?

No. Peptide Sciences shut down on March 6, 2026. The website displays only a shutdown notice. No orders can be placed and no refund process has been communicated.

Why did Peptide Sciences shut down?

A 15-month FDA enforcement wave targeting grey-market peptide vendors. The ITC blocked tirzepatide imports. Eli Lilly and Novo Nordisk filed lawsuits. Criminal cases resulted in millions in forfeitures. Peptide Sciences sold the GLP-1 compounds that drew the heaviest action.